Sanofi Basic EPS 2010-2024 | SNY
Sanofi annual/quarterly basic eps history and growth rate from 2010 to 2024. Basic eps can be defined as a company's net earnings or losses attributable to common shareholders per basic share basis.
- Sanofi basic eps for the quarter ending September 30, 2024 was $1.24, a 12.76% increase year-over-year.
- Sanofi basic eps for the twelve months ending September 30, 2024 was $1.96, a 49.25% decline year-over-year.
- Sanofi annual basic eps for 2023 was $0.002B, a 33.83% decline from 2022.
- Sanofi annual basic eps for 2022 was $0.004B, a 19.86% increase from 2021.
- Sanofi annual basic eps for 2021 was $0.003B, a 47.58% decline from 2020.
| Sanofi Annual Basic EPS |
| 2023 |
$2.33 |
| 2022 |
$3.52 |
| 2021 |
$2.94 |
| 2020 |
$5.61 |
| 2019 |
$1.25 |
| 2018 |
$2.04 |
| 2017 |
$3.79 |
| 2016 |
$2.03 |
| 2015 |
$1.82 |
| 2014 |
$2.22 |
| 2013 |
$1.87 |
| 2012 |
$2.42 |
| 2011 |
$2.83 |
| 2010 |
$2.85 |
| 2009 |
$2.77 |
| Sanofi Quarterly Basic EPS |
| 2024-09-30 |
$1.24 |
| 2024-06-30 |
$0.48 |
| 2024-03-31 |
$0.49 |
| 2023-12-31 |
$-0.25 |
| 2023-09-30 |
$1.10 |
| 2023-06-30 |
$0.63 |
| 2023-03-31 |
$0.86 |
| 2022-12-31 |
$1.29 |
| 2022-09-30 |
$0.84 |
| 2022-06-30 |
$0.50 |
| 2022-03-31 |
$0.90 |
| 2021-09-30 |
$1.09 |
| 2021-06-30 |
|
| 2021-03-31 |
$0.75 |
| 2020-09-30 |
$0.91 |
| 2020-03-31 |
$0.75 |
| 2019-09-30 |
$0.78 |
| 2019-03-31 |
$0.52 |
| 2018-03-31 |
$0.50 |
| 2017-12-31 |
$0.20 |
| 2017-09-30 |
$0.74 |
| 2017-06-30 |
$0.45 |
| 2017-03-31 |
$2.41 |
| 2016-12-31 |
$0.33 |
| 2016-09-30 |
$0.73 |
| 2016-06-30 |
$0.51 |
| 2016-03-31 |
$0.46 |
| 2015-09-30 |
$0.70 |
| 2015-06-30 |
$0.55 |
| 2014-06-30 |
$0.41 |
| 2013-06-30 |
$0.22 |
| 2012-06-30 |
$0.57 |
| 2012-03-31 |
$0.91 |
| 2011-12-31 |
$0.71 |
| 2011-09-30 |
$1.05 |
| 2011-06-30 |
$0.56 |
| 2011-03-31 |
$1.22 |
| 2010-12-31 |
$0.22 |
| 2010-09-30 |
$0.85 |
| 2010-06-30 |
$0.85 |
| 2010-03-31 |
$1.23 |
| 2009-12-31 |
$0.63 |
| 2009-09-30 |
$1.26 |
| 2009-06-30 |
$1.24 |
| 2009-03-31 |
$1.08 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$121.816B |
$46.611B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
